Health & Fitness
Health and Fitness
Health and Fitness
Mon, August 9, 2010Fri, August 6, 2010Thu, August 5, 2010Wed, August 4, 2010Tue, August 3, 2010Mon, August 2, 2010Fri, July 30, 2010Thu, July 29, 2010Wed, July 28, 2010Tue, July 27, 2010Mon, July 26, 2010Fri, July 23, 2010Thu, July 22, 2010Wed, July 21, 2010Tue, July 20, 2010Mon, July 19, 2010ArQule to Report Second Quarter 2010 Financial Results on August 4, 2010
Published in Health and Fitness on Wednesday, July 28th 2010 at 13:10 GMT by Market Wire
WOBURN, Mass.--([ BUSINESS WIRE ])--ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the second quarter of 2010 in a press release to be issued on Wednesday, August 4, 2010 at 7:00 a.m. eastern time. The Company will host a conference call at 9:00 a.m. eastern time that day to discuss these results.
Conference Call and Webcast | ||
| Date: | Wednesday, August 4, 2010 | |
| Time: | 9:00 a.m., Eastern Time | |
Conference Call Numbers | ||
| Domestic (toll free): | (877) 868-1831 | |
| International: | (914) 495-8595 | |
| Webcast: | [ www.arqule.com ] | |
A replay of the conference call will be available beginning at Noon on August 4, 2010 for seven days and can be accessed by dialing toll-free (800) 642-1687 and outside the U.S. (706) 645-9291. The confirmation code for replayed calls is 87797623.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Companya™s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQulea™s lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Companya™s pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQulea™s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIPa"), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. These include a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR).
